Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Background PLASMA PROTEIN BINDING Protocol
Document related concepts
Discovery and development of direct Xa inhibitors wikipedia , lookup
Discovery and development of integrase inhibitors wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
Discovery and development of non-nucleoside reverse-transcriptase inhibitors wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Pharmacognosy wikipedia , lookup
Neuropharmacology wikipedia , lookup
Plateau principle wikipedia , lookup
Drug interaction wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Discovery and development of cyclooxygenase 2 inhibitors wikipedia , lookup
Drug discovery wikipedia , lookup
Transcript
PLASMA PROTEIN BINDING Background Protocol Drugs may bind to a wide variety of plasma proteins, including Compound requirements albumin, and the degree of binding can impact on the pharmacokinetics and pharmacodynamics parameters of a drug, given that only the free drug in plasma is available to elicit a pharmacological effect and only free drug is available to be cleared. Hence it is important to measure plasma protein binding during the drug discovery phase. The leading approach for assessing plasma protein binding is rapid equilibrium dialysis as the impact of non-specific binding is 10mM DMSO solution, 10uL Test Article 5µM (Other concentrations available for high protein bound compounds) Incubation Time 4 hours at 37°C and 5% CO2 under continuous shaking minimised when compared to other methods such as ultrafiltration Test System equilibrium. 100% plasma and HT-Dialysis, which are relatively slow processes to reach Sygnature’s Plasma Protein Binding assay utilises the Rapid Equilibrium Dialysis (RED) device to measure the percentage binding of a test compound to plasma proteins in a variety of species (e.g. human, rat, dog, mouse, monkey). This will then allow the percentage unbound to be calculated. Test compounds and positive controls (species dependent) are incubated in 100% plasma and dialysed against buffer in a RED device for 4 hours at 37°C in a 5% CO2 incubator, with continuous shaking at 200 rpm. Samples are matrix matched and analysed by LC-MS/MS against a 6 point standard curve prepared with 100 % plasma. Equilibrium dialysis in the RED Device at Replicates Triplicate Analysis Method LC-MS/MS Controls 2 positive controls (species dependent) Data Delivery Percentage bound/unbound and percentage recovery Results Figure 1 Graph showing the percentage of plasma protein binding using 100% plasma, and their comparison to literature values (1) Obach, 1999, DMD 27:1350 and (2) RxList. About us The DMPK & Physical Sciences department at Sygnature Discovery is dedicated to understanding and optimising the absorption, distribution, metabolism and excretion of drug candidates by working in close partnership with clients and other departments within Sygnature to provide successful optimisation strategies. We have extensive know-how and expertise to provide well validated, state-of-the-art assays and a comprehensive applied consultancy service for interpretation of the in vitro ADME and in vivo PK data. Our corporate vision is to accelerate the discovery of new medicines, from the laboratory into development to treat patients. Our DMPK mission is to deliver tailored DMPK expertise through innovation, quality and commitment. Sygnature Discovery Limited BioCity Pennyfoot Street Nottingham NG1 1GF United Kingdom Telephone: +44 1159415401 Email: [email protected]
